Multimonth Subscription Pricing Model Introduced for Wegovy to Support Long-Term Treatment

Novo Nordisk has introduced a first-of-its-kind multimonth subscription program for semaglutide (Wegovy), designed to reduce cost barriers and improve long-term adherence among self-pay patients with obesity.¹ The new multimonth subscription pricing model offers savings of up to $1200 annually and expanded access through telehealth platforms. The program provides predictable monthly pricing, flexible subscription durations, and broader distribution channels, aiming to address persistent accessibility challenges in obesity management. This initiative reflects a growing emphasis on affordability and continuity in chronic disease treatment models.

The subscription model is available through multiple telehealth providers, including Ro, WeightWatchers, and LifeMD, with additional platforms expected to follow. Eligible self-pay patients can select 3-, 6-, or 12-month subscription plans, with longer commitments associated with lower monthly costs. Pricing varies by formulation and duration. For injectable Wegovy, monthly costs range from $329 (3-month plan) to $249 (12-month plan), while oral formulations’ costs range from $289 (3-month plan) to $249 (12-month plan). The program specifically targets patients without insurance coverage or those facing high out-of-pocket costs, as this is a population currently often excluded from sustained pharmacologic obesity treatment. Furthermore, insurance coverage for glucagon-like peptide-1 (GLP-1) therapies remains inconsistent, with approximately 60% of large employers and only 30% of small companies currently offering any form of coverage for these medications.²

The timing of this initiative coincides with the recent market entry of oral semaglutide (Wegovy). On a cash-pay basis, oral formulations are currently less expensive than their injectable counterparts, though insurance pricing remains largely equivalent between the two.² With the subscription pricing, the oral formulation is less expensive for the shorter 3-month subscription plan but equivalent to the injectable at the 12-month plan.

At the start of the year, GoodRx has also moved to expand access to oral semaglutide through its telemedicine platform, GoodRx for Weight Loss, offering the 2 lowest doses of the medication (1.5 mg and 4 mg) at $149 per month through April 2026, with higher doses priced at $299 monthly.³ These parallel access initiatives signal a broader industry shift toward more consumer-friendly pricing structures for GLP-1 therapies, and increased competition from additional oral agents expected to reach the market over the next 18 months may drive costs down further.²

The need for such approaches is underscored by recent survey data. A nationwide Navitus Health Solutions Pulse Survey of 2000 GLP-1 users found that 68% reported cost influenced their decision to start or continue treatment, 24% paid more than $250 per prescription fill, and 44% said costs exceeded their expectations.⁴ Notably, 60% of survey respondents reported knowing someone who wanted to take a GLP-1 medication but could not afford it, further illustrating the breadth of the access gap. Nearly 40% of GLP-1 users have already turned to manufacturer coupons or discount programs to manage expenses, reflecting the degree to which patients are actively seeking relief from out-of-pocket burden.⁴ These findings highlight the extent to which financial burden shapes treatment decisions across this drug class.

Obesity is recognized as a chronic, relapsing disease influenced by biological, environmental, and social factors, and it therefore requires sustained intervention rather than episodic treatment. The introduction of a subscription-based pricing model represents a shift in how chronic disease therapies, particularly high-cost agents like GLP-1 receptor agonists, are delivered.

The program’s structure emphasizes continuity and aligns with clinical guidance recommending sustained therapy for durable weight loss and cardiometabolic benefit. Furthermore, integration with telehealth platforms reflects evolving care delivery models and may expand reach, particularly for underserved populations.

Cost remains one of the most significant barriers to long-term adherence. Studies have shown that discontinuation of anti-obesity medications is often driven by financial constraints, limiting the durability of weight loss and associated cardiometabolic benefits.⁵ By addressing cost predictability, this model may improve persistence and, ultimately, clinical outcomes.

Looking forward, this model may serve as a blueprint for other chronic therapies, especially in cardiometabolic disease. Future research should evaluate whether such pricing strategies translate into measurable improvements in adherence, weight loss outcomes, and cardiovascular risk reduction.

References

1. Novo Nordisk launches first and only multi-month subscription program for FDA-approved Wegovy, offering savings of up to $1,200/year. News release. Novo Nordisk. March 31, 2026. Accessed March 31, 2026. https://www.prnewswire.com/news-releases/novo-nordisk-launches-first-and-only-multi-month-subscription-program-for-fda-approved-wegovy-offering-savings-of-up-to-1-200year-302729943.html

2.Grossi G, Levin E. Navigating GLP-1 costs with Eric Levin: insurance, cash pay, and the oral Wegovy shift. AJMC^®. February 19, 2026. Accessed April 1, 2026. https://www.ajmc.com/view/navigating-glp-1-costs-with-eric-levin-insurance-cash-pay-and-the-oral-wegovy-shift

3. Shaw ML. GoodRx to match Novo Nordisk price for oral semaglutide. AJMC. January 5, 2026. Accessed April 1, 2026. https://www.ajmc.com/view/goodrx-to-match-novo-nordisk-price-for-oral-semaglutide

4. Steinzor P. Rising costs cited by 68% of GLP-1 users as a major treatment barrier. AJMC. February 24, 2026. Accessed April 1, 2026. https://www.ajmc.com/view/rising-costs-cited-by-68-of-glp-1-users-as-a-major-treatment-barrier

5. Gasoyan H, Butsch WS, Casacchia NJ, et al. Reasons for discontinuation of obesity pharmacotherapy with semaglutide or tirzepatide in clinical practice. Obesity (Silver Spring). 2025;33(12):2296-2303. doi:10.1002/oby.70058